Drug references for physicians
Concise 2026 references for high-impact agents in modern practice. Each page covers FDA-approved indications, adult dosing (with renal and hepatic adjustments), contraindications and boxed warnings, the pivotal trial and guideline position, and a cross-system reasoning paragraph. Every drug page links to primary FDA label text and the PubMed record for each trial referenced.
For US-licensed physicians. Not a substitute for the full prescribing information. Dosing in special populations should be verified against the most current FDA label.
GLP-1 and dual GIP/GLP-1 receptor agonists
Cardiometabolic agents with expanding indications across diabetes, obesity, HFpEF, and kidney disease.
SGLT2 inhibitors
Foundational therapy across T2DM, heart failure (all EF), and chronic kidney disease.
Mineralocorticoid receptor antagonists
Steroidal and nonsteroidal MRAs with cardiovascular, renal, and endocrine indications.
Heart failure pillars (ARNI)
Neurohormonal therapies paired with beta-blockade, MRA, and SGLT2 inhibition.
Anticoagulants
Direct oral anticoagulants for AFib stroke prevention and venous thromboembolism.
Anti-amyloid antibodies
Disease-modifying therapies for early Alzheimer disease, with ARIA-directed monitoring.
MASH therapies
First-in-class agents for metabolic dysfunction-associated steatohepatitis.
Antiretrovirals
Long-acting injectable agents reshaping HIV prevention and maintenance therapy.
Antipsychotics
Atypical agents with long-acting injectable options for psychotic and mood disorders.
Antidepressants (rapid-acting)
Glutamatergic agents for treatment-resistant depression and acute suicidality.